Overview
Wavelet Medical develops a non-invasive, AI-powered fetal monitoring platform that uses abdominal EEG sensors to directly measure fetal brain activity during labor. Signals collected from the mother's abdomen are processed by proprietary AI algorithms to reconstruct the fetal EEG, enabling real-time assessment of the baby’s neurological health. This approach aims to detect early signs of distress such as hypoxia, potentially reducing preventable brain injuries at birth and lowering unnecessary Cesarean sections. The product is designed for hospital and healthcare-system customers (B2B) and is undergoing pre-clinical and early clinical testing at sites including Yale, LA General/USC, and Yonsei. Wavelet Medical seeks to translate academic research into a commercial, globally distributable solution through partnerships like its seed round with Aegis Ventures.
Work here?Claim your company
Simplify's take
What believers are saying
- ARPA-H funding through June 2027 pays for validation without immediate revenue pressure.
- Yale, LA General, USC, and Yonsei sites provide credible multicenter evidence and references.
- Reducing unnecessary C-sections offers hospitals immediate cost savings and stronger adoption economics.
What critics are saying
- Wavelet still lacks FDA clearance; hospitals will not adopt unapproved obstetric devices.
- Three-site studies with roughly 300 patients remain too small for delivery-room standard-of-care claims.
- If fetal EEG accuracy misses hypoxia, labor harms and litigation destroy trust before commercialization.
What makes Wavelet Medical unique
- Yale spinout Wavelet combines transabdominal EEG with proprietary AI, not fetal heart-rate proxies.
- ARPA-H awarded $2.14497 million on June 16, 2026, validating its neurologic readout.
- Aegis Ventures co-created commercialization on April 14, 2026, adding seed capital and hospital distribution.
Help us improve and share your feedback! Did you find this helpful?